Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07197450 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of XH02 for the Treatment of Hypoparathyroidism

Study acronym: XH02
StatusSuspended
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment suspended Sponsor's reason: Enrollment temporarily suspended in accordance with a newly implemented regulation, State Council Decree No. 818, on clinical research and clinical translation of new biomedical technologies; pending review and approval. Primary completion pushed from Jul 15, 2026 to May 30, 2027 · Completion pushed from Jul 30, 2026 to Aug 30, 2027 · Secondary endpoints: details revised at 1 of 10 entries · 2 more Show 5 more changesShow less
    • Primary completion pushed from Jul 15, 2026 to May 30, 2027
    • Completion pushed from Jul 30, 2026 to Aug 30, 2027
    • Secondary endpoints: details revised at 1 of 10 entries
    • Site details revised
    • Eligibility criteria expanded, about 2 words
  2. Primary completion pushed from Apr 15, 2026 to Jul 15, 2026 Completion pushed from Apr 30, 2026 to Jul 30, 2026 · Eligibility criteria shortened, about 66 wordsv4 Show 2 more changesShow less
    • Completion pushed from Apr 30, 2026 to Jul 30, 2026
    • Eligibility criteria shortened, about 66 words

    See this version in full on ClinicalTrials.gov ↗

  3. Primary completion date: Dec 31, 2025 to Apr 15, 2026 Completion date: Mar 31, 2026 to Apr 30, 2026v3 Show 1 more changeShow less
    • Completion date: Mar 31, 2026 to Apr 30, 2026
  4. Re-verified, no change to tracked fieldsv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to evaluate the safety and efficacy of a novel PTH replacement therapy drug in patients with hypoparathyroidism. The drug is an mRNA drug which will be translated into PTH after intravenous administration, to achieve the therapeutic effect.
Trial Details
NCT Number NCT07197450
Lead Sponsor Peking Union Medical College Hospital
Conditions Hypoparathyroidism
Enrollment 6 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov